Cancer Medicine: Big news for cancer patients. To cut down on the expenses associated with cancer treatment, the national government has opted to enhance price regulations on non-scheduled cancer medications. As per the government’s directive, the profit margins on the distribution and sale of these drugs will be restricted to 30% of the highest retail price (MRP). This move is anticipated to lower the prices of certain medications by as much as 70%, potentially saving cancer patients around Rs 2,500 crore annually.
Cancer Medicine Price to reduce?
The government’s recent initiative aims to rein in the costs of pricey cancer drugs. By endorsing a cap on the profit margin for the distribution and sale of non-listed cancer drugs at 30% of the maximum retail price (MRP), the government anticipates a substantial decrease in drug prices by up to 70%, resulting in an annual saving of around Rs 2,500 crore for cancer patients.
Additional Information
The Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers revealed that the National Pharmaceutical Pricing Authority (NPPA) discovered an average markup of roughly 170% on non-listed cancer drugs. In certain instances, this markup was as high as 700% or more, leading to a considerable price gap between the drug’s supply chain and its final cost to the patient.
Price disparities have been noted when purchasing medications from retail pharmacies, hospital pharmacies, and online drugstores. The new regulations seek to curb unjustified price hikes and alleviate financial strain on patients.
Scope of the Decision
The new regulation targets non-listed cancer drugs not covered by the government’s price-controlled list, encompassing both branded and generic drugs, domestically made or imported, patented or non-patented. The selection of drugs subject to these regulations will be determined by an expert committee formed under the Directorate General of Health Services (DGHS), with the National Pharmaceutical Pricing Authority issuing specific guidelines through notifications.
Previous Relief Measures
In February 2019, the government imposed profit margin restrictions on 42 non-scheduled cancer drugs, resulting in a 91% reduction in the maximum retail price of 526 drug brands, leading to annual savings of approximately Rs 984 crore. This recent decision seeks to replicate the success of that initiative on a larger scale. Manufacturers are required to maintain their current production levels to ensure a steady supply of medications.
Read More: Flipkart Big Billion Days Sale – Google Pixel 10a Gets ₹16,000 Discount, Know the Full Offer
The financial burden of cancer treatment in India is substantial and stressful for affected families. Therefore, this government action is a significant relief for families grappling with the economic challenges brought on by cancer.